

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	HAQUE ET AL.	Examiner:	SPIVACK, P.G.
Serial No.:	10/729,276	Group Art Unit:	1614
Filed:	DECEMBER 3, 2003	Docket No.:	12695.13USD2
Confirmation No.:	1586	Customer No.:	23552
Title:	TREATMENT OF CEREBROVASCULAR DISEASE		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(c))

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits or a first Office Action after filing a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113; ii) a Notice of Allowance under 37 C.F.R. § 1.311; or iii) an action that otherwise closes prosecution on the application. Our Deposit Account No. 13-2725 is being charged in the amount of \$180.00 for consideration of the items listed on the enclosed Form 1449.

A copy of any foreign patent document or "Other Document" listed on the Form 1449 is enclosed, in accordance with 37 C.F.R. §1.98(a)(2). Because this application was filed after June 30, 2003, copies of the U.S. Patents and U.S. patent publications listed on the enclosed Form 1449 are not provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a

reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: _____

8-10-2007



Brian R. Dorn
Reg. No. 57,395

23552

PATENT TRADEMARK OFFICE

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12695.13USD2	Application Number: 10/729,276
	Applicant: Haque	
	Filing Date: December 3, 2003	Group Art Unit: 1614

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,043,259	3/28/2000	Dhalla et al.			
	6,051,585	04/18/2000	Dakashnamurti et al.			
	6,339,085 B1	01/15/2002	Haque			
	6,417,204 B1	07/09/2002	Haque			
	6,489,345	12/3/2002	Sethi			
	6,548,519 B1	04/15/2003	Haque			
	6,586,414	7/1/2003	Haque et al.			
	6,605,612 B2	08/12/2003	Haque			
	6,667,315 B2	12/23/2003	Haque			
	6,677,356	1/13/2004	Sethi et al.			
	6,780,997 B2	08/24/2004	Haque			
	6,861,439 B2	03/01/2005	Haque et al.			
	6,867,215 B2	03/15/2005	Haque			
	6,890,943 B2	05/10/2005	Haque			
	6,897,228 B2	05/24/2005	Haque			
	7,105,673 B2	09/12/2006	Haque			
	7,115,625 B2	10/03/2006	Sethi et al.			
	7,115,626 B2	10/03/2006	Sethi et al.			
	7,125,889 B2	10/24/2006	Sethi et al.			
	7,132,430 B2	11/07/2006	Sethi et al.			
	7,144,892 B2	12/05/2006	Sethi et al.			
	7,148,233 B2	12/12/2006	Sethi et al.			
	7,230,009 B2	06/12/2007	Haque et al.			
	2004/0186077	09/23/2004	Diakur et al.			
	10/215,739		Sethi			8-8-2002
	10/549,505					
	10/551,302					
	10/551,303					
	10/584,332					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in compliance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12695.13USD2	Application Number: 10/729,276
	Applicant: Haque	
	Filing Date: December 3, 2003	Group Art Unit: 1614

	10/732,037					
	10/881,864		Sethi			6-30-2004
	10/974,707					
	10/974,718					
	11/016,737					
	11/177,248					
	11/202,272		Friesen			8-10-2005
	11/262,509					
	11/288,971					
	11/326,201					
	11/424,069		Friesen			6-14-2006
	11/569,192					
	11/631,726					
	11/662,351					
	11/663,824					
	11/672,140					
	11/720,422					
	11/739,920					

FOREIGN PATENT DOCUMENTS

DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Bässler, "Megavitamin Therapy with Pyridoxine", <i>Internat. J. Vit. Nutr. Res.</i> 58: 105-118 (1988)
	Bonaa et al., "Homocysteine lowering and cardiovascular events after acute myocardial infarction", <i>N. Eng. J. Med.</i> 354: (2006); DOI:10.1056/NEJM01055227 (including supplementary appendix)
	Chumnanantana et al., "Vitamin B ₆ compounds prevent the death of yeast cells due to menadione, a reactive oxygen generator", <i>Biochimica et Biophysica Acta</i> 1722:84-91 (2005)
	Higuchi et al., "Aminophospholipid glycation and its inhibitor screening system: A new role of pyridoxal 5'-phosphate and pyridoxal as lipid glycation inhibitor", <i>J Lipid Res.</i> 2006 Feb 9; doi:10.1194/jlr.M500348-JLR200.
	Hirai et al., "Cerebrospinal fluid somatostatin in West syndrome: changes in response to combined treatment with high-dose pyridoxal

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12695.13USD2	Application Number: 10/729,276
	Applicant: Haque	
	Filing Date: December 3, 2003	Group Art Unit: 1614

	phosphate and low-dose corticotropin", <i>Neuropeptides</i> 32(6):581-586 (1998)
	Holman, "Pyridoxine - Vitamin B-6", <i>J. Austral. Coll. Nutr. Environ. Med.</i> 14: 5-16 (1995)
	Kannan et al., "Effect of Vitamin B6 on oxygen radicals, mitochondrial membrane potential, and lipid peroxidation in H2O2-treated U937 monocytes", <i>Free Radical Biol. Med.</i> 36: 423-428 (2004).
	Kolata, "Studies suggest B vitamins don't prevent heart attacks", <i>N.Y. Times</i> , March 13, 2006 at page 14, section A, column 3.
	Kuo et al. "Pyridoxal phosphate-responsive epilepsy with resistance to pyridoxine", <i>Pediatr. Neurol.</i> 26: 146-147 (2002)
	Ohtsuka et al., "Treatment of the West Syndrome with High-Dose Pyridoxal Phosphate", <i>Brain & Development</i> 9(4):418-421 (1987)
	Schaumburg et al., "Sensory neuropathy from pyridoxine abuse", <i>N. Eng. Med. J.</i> 309: 445-448 (1983)
	Seki, "Combination Treatment of High-Dose Pyridoxal Phosphate and Low-Dose ACTH in Children with West Syndrome and Related Disorders", <i>The Japanese Journal of Psychiatry and Neurology</i> 44(2):219-237 (1990)
	Ubbink et al., "Effect of different levels of oral pyridoxine supplementation on plasma pyridoxal-5'-phosphate and pyridoxal levels and urinary vitamin B-6 excretion," <i>Am. J. Clin. Nutr.</i> 46: 78-85 (1987)
	Wang et al., "Pyridoxal phosphate is better than pyridoxine for controlling idiopathic intractable epilepsy" <i>Arch. Dis. Child.</i> 90: 512-515 (2005)
	The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators, "Homocysteine lowering with folic acid and B vitamins in vascular disease" <i>N. Eng. J. Med.</i> 354: (2006); DOI:10.1056/NEJM060900 (including supplementary appendix)
	"Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline" A Report on the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline and Subcommittee on Upper Reference Levels of Nutrients, Food and Nutrition Board, Institute of Medicine (1998) (ISBN 0-309-06554-2)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	